Therefore, this article will elucidate the fundamental therapeutic mechanism behind peptide-based cancer vaccination for breast cancer, HER2/neu-based vaccination using GM-CSF as the adjuvant, and specifically discuss the clinical outcomes of this vaccination. This evidence concerns the gene ERBB2 and breast carcinoma.